scispace - formally typeset
B

Berihun M. Zeleke

Researcher at Monash University

Publications -  36
Citations -  5905

Berihun M. Zeleke is an academic researcher from Monash University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 16, co-authored 32 publications receiving 4612 citations. Previous affiliations of Berihun M. Zeleke include University of Gondar & Alfred Hospital.

Papers
More filters
Journal ArticleDOI

Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

Haidong Wang, +844 more
- 08 Oct 2016 - 
TL;DR: The Global Burden of Disease 2015 Study provides a comprehensive assessment of all-cause and cause-specific mortality for 249 causes in 195 countries and territories from 1980 to 2015, finding several countries in sub-Saharan Africa had very large gains in life expectancy, rebounding from an era of exceedingly high loss of life due to HIV/AIDS.
Journal ArticleDOI

Adverse birth outcomes among deliveries at Gondar University Hospital, Northwest Ethiopia

TL;DR: Prevalence of adverse birth outcomes (still birth, preterm birth and low birth weight) were high and still a major public health problem in the area and further enhancements of ante natal and maternal care and early screening for hypertension are recommended.
Journal ArticleDOI

Incidence and correlates of low birth weight at a referral hospital in Northwest Ethiopia

TL;DR: Efforts should to enhance national antenatal care utilization in general, and particularly in Gondar, should be encouraged as its absence is closely associated with LBW.
Journal ArticleDOI

Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia

TL;DR: Non-adherence to anti-tuberculosis treatment was high and special attention should be given to symptomatic patients, TB/HIV co-infected patients, and those in the continuation phase of the tuberculosis therapy.